Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, discusses the benefits of not preferencing a CD19 CAR construct in patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). Lymphodepleting regimens can vary depending on the specific CAR-T, and the disease and patient characteristics will have an impact on outcomes. Prof. Subklewe additionally highlights propensity score matching and personalized approaches to enhance survival in patients. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.